Assistant Professor
Dermatology
Dr. Kenneth Y. Tsai, MD
|
|
Give Review
Kenneth Y. Tsai, MD works in the field of Dermatology. He graduated from Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School has a rank of 1 in research and a 12 in primary care He has 3 awards "AACR Landon Foundation Cancer Prevention Award", "Chief Resident, Dermatology" and "Medical Scientist Training Program". Kenneth Tsai is a published physician. He has 40 papers published. The most current publication "Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos." Kenneth Tsai accepts Medicare payments and is registered with Medicare.gov.
Publications
- When "Effective" Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design.
- Molecular cancer prevention: Current status and future directions.
- Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine.
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
- IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.
- Mutational landscape of aggressive cutaneous squamous cell carcinoma.
- The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF.
- Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy.
- Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD.
- Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.
- Induced multipotency in adult keratinocytes through down-regulation of ΔNp63 or DGCR8.
- Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.
- Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma.
- Drug safety evaluation of vemurafenib in the treatment of melanoma.
- Assessing the treatment of nonmelanoma skin cancers.
- Kaposi sarcoma presenting as a cutaneous horn.
- Dynamic gene expression analysis links melanocyte growth arrest with nevogenesis.
- Lues maligna in early HIV infection case report and review of the literature.
- TAp63 prevents premature aging by promoting adult stem cell maintenance.
- Remote assessment of acne: the use of acne grading tools to evaluate digital skin images.
- Nodular presentation of secondary syphilis.
- Systemic adjuvant therapy for patients with high-risk melanoma.
- Primer on the human genome.
- A potential pathogenic role for aberrant DNA rearrangements in bridging dyscrasias of undetermined significance and lymphoma?
- Evidence-based medicine: do we use guidelines or mindlines? Commentary on: Evidence-based guidelines or collectively constructed "mindlines?" ethnographic st...
- The genetics of skin cancer.
- ARF mutation accelerates pituitary tumor development in Rb+/- mice.
- BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling.
- Collagenous vasculopathy: a report of three cases.
- ARF is not required for apoptosis in Rb mutant mouse embryos.
- p63 and p73 are required for p53-dependent apoptosis in response to DNA damage.
- Role for the p53 homologue p73 in E2F-1-induced apoptosis.
- Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos.
- An intact HDM2 RING-finger domain is required for nuclear exclusion of p53.
- Expression of cyclins E1 and E2 during mouse development and in neoplasia.
- MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability.
- Analysis of cell mechanics in single vinculin-deficient cells using a magnetic tweezer.
- Extracellular matrix and pulmonary hypertension: control of vascular smooth muscle cell contractility.
- BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Schools
Harvard Medical School
Massachusetts General Hospital
Harvard Medical School Combined ProgramMassachusetts General Hospital
Harvard Medical School Combined Program
Doctors Specialties
- Dermatopathology
- Dermatology
Accepted Insurances
Awards
- AACR Landon Foundation Cancer Prevention Award
- Chief Resident, Dermatology
- Medical Scientist Training Program
Education
-
Beth Israel Deaconess Medical Center -
Massachusetts General Hospital -
Harvard Medical School -
Yale College
Hospital
-
University of Texas M.D. Anderson Cancer Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1699801308 |
| Last Name Of The Provider | TSAI |
| First Name Of The Provider | KENNETH |
| View All |
Similar Doctors
|
|
Dr. Audrey J. Chan, MD |
|
Dr. Katherine M. Cox, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adrienne S. Glaich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Troy D. Felber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald P. Rapini, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria I. Colome, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela M. Davis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Josef F. Doenges, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Reena P. Jogi, MD
This Doctor is OpenDoctor Recommended.
|